| $385M | ||
| $350M | ||
| $215M | ||
| $100M | ||
| $83M | ||
| $63M |
Buys | $0 | 0 | 0 |
Sells | $10,580,137 | 29 | 100 |
| FENTON DENNIS M | director | 0 | $0 | 1 | $72,270 | $-72,270 |
| Ware J. Anthony | director | 0 | $0 | 1 | $193,343 | $-193,343 |
| Lizzul Paul F. | Chief Medical Officer | 0 | $0 | 4 | $521,526 | $-521,526 |
| Marquet Magda | director | 0 | $0 | 1 | $530,531 | $-530,531 |
| RENTON HOLLINGS | director | 0 | $0 | 3 | $766,174 | $-766,174 |
| Schmid John P. | director | 0 | $0 | 1 | $1.16M | $-1.16M |
| MULROY DENNIS | CHIEF FINANCIAL OFFICER | 0 | $0 | 5 | $1.55M | $-1.55M |
| Faga Daniel | President, CEO | 0 | $0 | 4 | $2.81M | $-2.81M |
| LOUMEAU ERIC J | CHIEF LEGAL OFFICER | 0 | $0 | 9 | $2.98M | $-2.98M |
AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of various dermatological inflammatory diseases; Rosnilimab, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through rosnilimab treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. and Bristol-Myers Squibb; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
Over the last 12 months, insiders at AnaptysBio, Inc. have bought $0 and sold $10.58M worth of AnaptysBio, Inc. stock.
On average, over the past 5 years, insiders at AnaptysBio, Inc. have bought $11.39M and sold $6.98M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 6,646 shares for transaction amount of $86,070 was made by EcoR1 Capital, LLC () on 2025‑01‑02.
| 2026-03-30 | Sale | Schmid John P. | director | 20,645 0.0728% | $56.11 | $1.16M | +11.26% | |
| 2026-03-27 | Sale | Faga Daniel | President, CEO | 17,679 0.066% | $61.61 | $1.09M | -3.38% | |
| 2026-02-11 | Sale | LOUMEAU ERIC J | CHIEF LEGAL OFFICER | 10,000 0.0353% | $54.00 | $540,000 | +9.18% | |
| 2026-01-15 | Sale | Marquet Magda | director | 11,000 0.0414% | $48.23 | $530,531 | +19.30% | |
| 2026-01-08 | Sale | Faga Daniel | President, CEO | 14,281 0.0526% | $44.71 | $638,504 | +25.71% | |
| 2026-01-08 | Sale | Lizzul Paul F. | Chief Medical Officer | 3,650 0.0135% | $44.71 | $163,192 | +25.71% | |
| 2026-01-08 | Sale | MULROY DENNIS | CHIEF FINANCIAL OFFICER | 2,515 0.0093% | $44.71 | $112,446 | +25.71% | |
| 2026-01-08 | Sale | LOUMEAU ERIC J | CHIEF LEGAL OFFICER | 2,210 0.0081% | $44.71 | $98,809 | +25.71% | |
| 2026-01-07 | Sale | Faga Daniel | President, CEO | 9,202 0.0334% | $45.11 | $415,102 | +21.77% | |
| 2026-01-07 | Sale | Lizzul Paul F. | Chief Medical Officer | 2,235 0.0081% | $45.11 | $100,821 | +21.77% | |
| 2026-01-07 | Sale | MULROY DENNIS | CHIEF FINANCIAL OFFICER | 1,908 0.0069% | $45.11 | $86,070 | +21.77% | |
| 2026-01-07 | Sale | LOUMEAU ERIC J | CHIEF LEGAL OFFICER | 9,639 0.0353% | $45.56 | $439,200 | +21.77% | |
| 2026-01-05 | Sale | Faga Daniel | President, CEO | 15,309 0.0554% | $43.26 | $662,267 | +27.11% | |
| 2026-01-05 | Sale | Lizzul Paul F. | Chief Medical Officer | 4,219 0.0153% | $43.26 | $182,514 | +27.11% | |
| 2026-01-05 | Sale | MULROY DENNIS | CHIEF FINANCIAL OFFICER | 3,363 0.0122% | $43.26 | $145,483 | +27.11% | |
| 2026-01-05 | Sale | LOUMEAU ERIC J | CHIEF LEGAL OFFICER | 2,983 0.0108% | $43.26 | $129,045 | +27.11% | |
| 2025-12-23 | Sale | Ware J. Anthony | director | 3,900 0.0139% | $49.58 | $193,343 | +8.39% | |
| 2025-12-22 | Sale | Lizzul Paul F. | Chief Medical Officer | 1,500 0.0054% | $50.00 | $75,000 | +7.67% | |
| 2025-12-22 | Sale | MULROY DENNIS | CHIEF FINANCIAL OFFICER | 10,000 0.0359% | $50.00 | $500,000 | +7.67% | |
| 2025-12-22 | Sale | LOUMEAU ERIC J | CHIEF LEGAL OFFICER | 10,000 0.0366% | $51.00 | $510,000 | +7.67% |
| Faga Daniel | President, CEO | 495965 1.7252% | $33.99M | 0 | 7 | |
| Lizzul Paul F. | Chief Medical Officer | 42088 0.1464% | $2.88M | 0 | 10 | |
| Schmid John P. | director | 31622 0.11% | $2.17M | 0 | 1 | |
| MULROY DENNIS | CHIEF FINANCIAL OFFICER | 21852 0.076% | $1.5M | 0 | 11 | |
| LOUMEAU ERIC J | CHIEF LEGAL OFFICER | 12835 0.0446% | $879,710.90 | 0 | 21 | |
| Marquet Magda | director | 9930 0.0345% | $680,602.20 | 0 | 1 | |
| Ware J. Anthony | director | 9630 0.0335% | $660,040.20 | 1 | 1 | +16.44% |
| FENTON DENNIS M | director | 4965 0.0173% | $340,301.10 | 0 | 2 | |
| RENTON HOLLINGS | director | 4965 0.0173% | $340,301.10 | 0 | 6 | |
| EcoR1 Capital, LLC | 7880094 27.4107% | $540.1M | 13 | 0 | +22.23% | |
| NODELMAN OLEG | 7521024 26.1617% | $515.49M | 1 | 1 | +12.85% | |
| Novo Holdings A/S | 10 percent owner | 1936604 6.7364% | $132.73M | 1 | 8 | +59% |
| Topper James N | 1045031 3.6351% | $71.63M | 1 | 0 | +59% | |
| Frazier Healthcare V, LP | 10 percent owner | 311291 1.0828% | $21.34M | 1 | 0 | +59% |
| Frazier Healthcare VII, L.P. | 10 percent owner | 311291 1.0828% | $21.34M | 1 | 0 | +59% |
| Lydon Nicholas | director | 271106 0.943% | $18.58M | 1 | 1 | +59% |
| Suria Hamza | President, CEO | 68600 0.2386% | $4.7M | 0 | 10 | |
| Londei Marco | Chief Medical Officer | 22377 0.0778% | $1.53M | 0 | 3 | |
| Avalon Ventures VII L P | 10 percent owner | 0 0% | $0 | 0 | 1 | |
| Piscitelli Dominic | Chief Financial Officer | 0 0% | $0 | 0 | 1 |
$21,345,882 | 83 | 94.45% | $2.08B | |
$54,590,806 | 65 | 21.84% | $2.02B | |
$1,376,668 | 53 | 18.46% | $1.71B | |
$105,696,475 | 44 | 10.07% | $2.03B | |
$678,065,999 | 37 | -13.32% | $1.71B | |
$25,378,134 | 24 | 1.44% | $1.6B | |
$8,195,601 | 23 | -12.08% | $1.97B | |
$18,854,717 | 21 | 22.51% | $2.12B | |
AnaptysBio, Inc. (ANAB) | $135,656,796 | 20 | 30.66% | $1.97B |
$154,554,190 | 14 | 29.60% | $1.93B | |
$2,788,839 | 12 | 6.73% | $1.58B | |
$2,859,892 | 10 | 29.21% | $2.18B | |
$94,976,497 | 10 | -10.72% | $2.08B | |
$44,805,526 | 9 | 57.04% | $1.8B | |
$93,268,646 | 8 | -37.22% | $1.97B | |
$25,073,947 | 7 | -5.99% | $1.69B | |
$46,235,722 | 6 | -31.77% | $1.63B | |
$5,000,000 | 1 | -22.84% | $2.06B | |
$23,993,224 | 1 | 9.82% | $1.61B |
| Increased Positions | 87 | +41.43% | 3M | +9.66% |
| Decreased Positions | 92 | -43.81% | 6M | -18.81% |
| New Positions | 34 | New | 1M | New |
| Sold Out Positions | 26 | Sold Out | 2M | Sold Out |
| Total Postitions | 205 | -2.38% | 29M | -9.15% |
| Ecor1 Capital, Llc | $354,210.00 | 28.14% | 7.88M | 0 | 0% | 2025-09-30 |
| Point72 Asset Management, L.P. | $101,835.00 | 8.09% | 2.27M | -209,346 | -8.46% | 2025-09-30 |
| Blackrock, Inc. | $77,418.00 | 6.15% | 1.72M | -64,610 | -3.62% | 2025-09-30 |
| Morgan Stanley | $69,954.00 | 5.56% | 1.56M | -313,582 | -16.77% | 2025-09-30 |
| Millennium Management Llc | $68,289.00 | 5.43% | 1.52M | +1M | +646.4% | 2025-09-30 |
| Vanguard Group Inc | $66,391.00 | 5.28% | 1.48M | -60,561 | -3.94% | 2025-09-30 |
| Tang Capital Management Llc | $59,947.00 | 4.76% | 1.33M | +2,760 | +0.21% | 2025-09-30 |
| First Light Asset Management, Llc | $44,508.00 | 3.54% | 990,161 | -3M | -72.03% | 2025-09-30 |
| State Street Corp | $39,261.00 | 3.12% | 873,432 | +52,401 | +6.38% | 2025-09-30 |
| Assenagon Asset Management S.A. | $37,755.00 | 3% | 839,934 | +822,975 | +4,852.73% | 2025-09-30 |